Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma

Genes Chromosomes and Cancer

Volumn 52, Issue 9, 2013, Pages 785-793

  Alpar, Donat ^a   de Jong, Danielle ^b   Holczer Nagy, Zsofia ^a   Kajtar, Bela ^a   Savola, Suvi ^c   Jakso, Pal ^a   David, Marianna ^a   Kosztolanyi, Szabolcs ^a   Kereskai, Laszlo ^a   Pajor, Laszlo ^a   Szuhai, Karoly ^b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MRC HOLLAND   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BONE MARROW; CHROMOSOME 1; CHROMOSOME 13; CYTOGENETICS; DISEASE CLASSIFICATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; MAJOR CLINICAL STUDY; MALE; MONOSOMY; MULTIPLE MYELOMA; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; CYTOGENETIC ANALYSIS; DNA COPY NUMBER VARIATIONS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTIPLE MYELOMA; MULTIPLEX POLYMERASE CHAIN REACTION;

EID: 84880414009     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22074     Document Type: Article

References (34)

1. Abdool A, Donahue AC, Wohlgemuth JG, Yeh CH. 2010. Detection, analysis and clinical validation of chromosomal aberrations by multiplex ligation-dependent probe amplification in chronic leukemia. PLoS One 5:e15407.
2. Alpár D, de Jong D, Savola S, Yigittop H, Kajtár B, Kereskai L, Pajor L, Szuhai K. 2012. MLPA is a powerful tool for detecting lymphoblastic transforrmaion in chronic myeloid leukemia and revealing thee clonal origin of relapse in pediatric acute lymphoblastic leukemia. Cancer Genet 205:465-469.
3. Al Zaabi EA, Fernandez LA, Sadek IA, Riddell DC, Greer WL. 2010. Multiplex ligation-dependent probe amplification versus multiprobe fluorescence in situ hybridization to detect genomic aberrations in chronic lymphocytic leukemia: A tertiary center experience. J Mol Diagn 12:197-203.
4. Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL, Attal M, Marit G, Mathiot C, Facon T, Moreau P, Anderson KC, Campion L, Munshi NC, Minvielle S. 2009. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 27:4585-4590.
5. Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B, Decaux O, Lamy T, Legros L, Fuzibet JG, Michallet M, Corront B, Lenain P, Hulin C, Mathiot C, Attal M, Facon T, Harousseau JL, Minvielle S, Moreau P; Intergroupe Francophone du Myélome. 2011. Translocation t(14;16) and multiple myeloma: Is it really an independent prognostic factor? Blood117:2009-2011.
6. Balgobind BV, Hollink IH, Reinhardt D, van Wering ER, de Graaf SS, Baruchel A, Stary J, Beverloo HB, de Greef GE, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM. 2010. Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. Eur J Cancer 46:1892-1899.
7. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. 2005. Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood 106:296-303.
8. Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group. 2012. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: Analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26:349-355.
9. Buijs A, Krijtenburg PJ, Meijer E. (2006) Detection of risk-identifying chromosomal abnormalities and genomic profiling by multiplex ligation-dependent probe amplification in chronic lymphocytic leukemia. Haematologica 91:1434-1435.
10. Coll-Mulet L, Santidrián AF, Cosialls AM, Iglesias-Serret D, de Frias M, Grau J, Menoyo A, González-Barca E, Pons G, Domingo A, Gil J. 2008. Multiplex ligation-dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukaemia. Br J Haematol 142:793-801.
11. Donahue AC, Abdool AK, Gaur R, Wohlgemuth JG, Yeh CH. 2011. Multiplex ligation-dependent probe amplification for detection of chromosomal abnormalities in myelodysplastic syndrome and acute myeloid leukemia. Leuk Res 35:1477-1483.
12. Fabris S, Scarciolla O, Morabito F, Cifarelli RA, Dininno C, Cutrona G, Matis S, Recchia AG, Gentile M, Ciceri G, Ferrarini M, Ciancio A, Mannarella C, Neri A, Fragasso A. 2011. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in chronic lymphocytic leukemia: A comparative study. Genes Chromosomes Cancer 50:726-734.
13. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H; International Myeloma Working Group. 2009. International Myeloma Working Group molecular classification of multiple myeloma: Spotlightreview. Leukemia 23:2210-2221.
14. Gardiner RB, Morash BA, Riddell C, Wang H, Fernandez CV, Yhap M, Berman JN. 2012. Using MS-MLPA as an efficient screening tool for detecting 9p21 abnormalities in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 58:852-859.
15. Gutiérrez NC, Castellanos MV, Martín ML, Mateos MV, Hernández JM, Fernández M, Carrera D, Rosiñol L, Ribera JM, Ojanguren JM, Palomera L, Gardella S, Escoda L, Hernández-Boluda JC, Bello JL, de la Rubia J, Lahuerta JJ, San Miguel JF; GEM/PETHEMA Spanish Group. 2007. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 21:143-150.
16. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer J R, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD Jr. 2006. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108:1724-1732.
17. Hess CJ, Errami A, Berkhof J, Denkers F, Ossenkoppele GJ, Nygren AO, Schuurhuis GJ, Waisfisz Q. 2008. Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. Leuk Lymphoma 49:1132-1141.
18. Hörnig-Hölzel C, Savola S. 2012. Multiplex ligation-dependent probe amplification (MLPA) in tumor diagnostics and prognostics. Diagn Mol Pathol 21:189-206.
19. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ, Marra MA. 2009. Circos: An information aesthetic for comparative genomics. Genome Res 19:1639-1645.
20. López-Corral L, Sarasquete ME, Beà S, García-Sanz R, Mateos MV, Corchete LA, Sayagués JM, García EM, Bladé J, Oriol A, Hernández-García MT, Giraldo P, Hernández J, González M, Hernández-Rivas JM, San Miguel JF, Gutiérrez NC. 2012. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia (accepted)
21. Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S. 2011. Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood118:675-678.
22. Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrison H, Jones L, Masic D, Patel B, Rowe JM, Tallman M, Goldstone AH, Fielding AK, Harrison CJ. 2012. IGH at translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol 30:3100-3108.
23. Nagy Z, Kajtár B, Jáksó P, Dávid M, Kosztolányi S, Hermesz J, Kereskai L, Pajor L, Alpár D. 2011. Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level. Leuk Res 35:1114-1116.
24. Pérez-Simón JA, García-Sanz R, Tabernero MD, Almeida J, González M, Fernández-Calvo J, Moro MJ, Hernández JM, San Miguel JF, Orfão A. 1998. Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood 91:3366-3671.
25. Ross FM, Avet-Loiseau H, Ameye G, Gutiérrez NC, Liebisch P, O'Connor S, Dalva K, Fabris S, Testi AM, Jarosova M, Hodkinson C, Collin A, Kerndrup G, Kuglik P, Ladon D, Bernasconi P, Maes B, Zemanova Z, Michalova K, Michau L, Neben K, Hermansen NE, Rack K, Rocci A, Protheroe R, Chiecchio L, Poirel HA, Sonneveld P, Nyegaard M, Johnsen HE; on behalf of the European Myeloma Network. 2012. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 97:1272-1277.
26. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. 2002. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res30:e57.
27. Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP, Harrison CJ. 2010. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 49:1104-1113.
28. Stevens-Kroef M, Simons A, Gorissen H, Feuth T, Weghuis DO, Buijs A, Raymakers R, Geurts van Kessel A. 2009. Identification of chromosomal abnormalities relevant to prognosis in chronic lymphocytic leukemia using multiplex ligation-dependent probe amplification. Cancer Genet Cytogenet 195:97-104.
29. Stevens-Kroef M, Weghuis DO, Croockewit S, Derksen L, Hooijer J, Elidrissi-Zaynoun N, Siepman A, Simons A, Kessel AG. 2012. High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma. Genes Chromosomes Cancer 51:997-1006.
30. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. (Eds.). 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon. pp. 202-208.
31. Tapper W, Chiecchio L, Dagrada GP, Konn ZJ, Stockley DM, Szubert AJ, Gregory WM, Bell SE, Jackson GH, Child JA, Morgan GJ, Ross FM. 2011. Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myeloma. J Clin Oncol 29:e37-e39.
32. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR. 1995. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250-4256.
33. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr. 2006. The molecular classification of multiple myeloma. Blood 108:2020-2028.
34. Zojer N, Königsberg R, Ackermann J, Fritz E, Dallinger S, Krömer E, Kaufmann H, Riedl L, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J. 2000. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95:1925-1930.